

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM S-8**  
**REGISTRATION STATEMENT**  
*UNDER*  
*THE SECURITIES ACT OF 1933*

---

**SEATTLE GENETICS, INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**91-1874389**  
(I.R.S. Employer  
Identification Number)

**21823 30<sup>th</sup> Drive SE**  
**Bothell, Washington 98021**  
(Address of Principal Executive Offices) (Zip Code)

**Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan**  
(Full title of the plan)

**Clay B. Siegall, Ph.D.**  
**President and Chief Executive Officer**  
**Seattle Genetics, Inc.**  
**21823 30<sup>th</sup> Drive SE**  
**Bothell, Washington 98021**  
**(425) 527-4000**

(Name and address of agent for service) (telephone number, including area code, of agent for service)

*Copies to:*

**Jean Liu**  
**Executive Vice President,**  
**Legal Affairs & General Counsel**  
**Seattle Genetics, Inc.**  
**21823 30<sup>th</sup> Drive SE**  
**Bothell, Washington 98021**  
**(425) 527-4000**

**Chadwick L. Mills**  
**Cooley LLP**  
**101 California Street, 5<sup>th</sup> Floor**  
**San Francisco, CA 94111-5800**  
**(415) 693-2000**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
 Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company   
 Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**CALCULATION OF REGISTRATION FEE**

Title of Securities to be Registered	Amount to be Registered (1)	Proposed Maximum Offering Price Per Share (2)	Proposed Maximum Aggregate Offering Price (2)	Amount of Registration Fee
Common Stock, \$0.001 par value per share	6,000,000	\$70.60	\$423,600,000	\$52,739

- (1) Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant’s Common Stock.
- (2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant’s Common Stock as reported on The Nasdaq Global Select Market on July 20, 2018.

---

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by Seattle Genetics, Inc. (the "Registrant") for the purpose of registering an additional 6,000,000 shares of the Registrant's Common Stock to be issued pursuant to the Registrant's Amended and Restated 2007 Equity Incentive Plan (the "Plan"). The Registrant previously registered 27,000,000 shares of the Registrant's Common Stock reserved for issuance under the Plan pursuant to the Registrant's Registration Statements on Form S-8 (File Nos. 333-148188, 333-168672, 333-188446, 333-197992 and 333-212688), filed with the Securities and Exchange Commission on December 19, 2007, August 9, 2010, May 8, 2013, August 8, 2014 and July 26, 2016, respectively.

---

## PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

### Item 3. Incorporation of Documents by Reference.

The following documents have been filed by the Registrant with the Securities and Exchange Commission (the “Commission”) and are incorporated herein by reference:

- the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Commission on February 15, 2018 (the “2017 Form 10-K”);
- the information specifically incorporated by reference into the 2017 Form 10-K from the Registrant’s definitive proxy statement on Schedule 14A, filed with the Commission on April 4, 2018;
- the Registrant’s Quarterly Reports on Form 10-Q, filed with the Commission on April 26, 2018 and July 26, 2018;
- the Registrant’s Current Reports on Form 8-K, filed with the Commission on January 31, 2018 (except for the information furnished under Item 2.02 thereof), January 31, 2018, February 1, 2018, March 9, 2018 (as amended on May 21, 2018), March 15, 2018, March 20, 2018 and May 18, 2018; and
- the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A filed with the Commission on February 28, 2001, including any amendments or reports filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

### Item 4. Description of Securities.

Not applicable.

### Item 5. Interests of Named Experts and Counsel.

Not applicable.

### Item 6. Indemnification of Directors and Officers.

The Registrant’s fourth amended and restated certificate of incorporation, as amended, provides that the Registrant is authorized to indemnify its directors, officers and other agents through bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the Delaware General Corporation Law, subject only to limits created by applicable Delaware law (statutory or non-statutory), with respect to actions for breach of duty to a corporation, its stockholders, and others. In addition, the charter includes the elimination of liability for monetary damages to the Registrant and its stockholders for breach of fiduciary duty as a director. However, the Registrant’s directors may be personally liable for liability:

- for any breach of duty of loyalty to the Registrant or to its stockholders;

- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
- for unlawful payment of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law; or
- for any transaction from which the director derived an improper personal benefit.

In addition, the Registrant's amended and restated bylaws provide that:

- the Registrant is required to indemnify its directors and officers to the maximum extent and in the manner permitted by Delaware law, subject to limited exceptions;
- the Registrant is required to advance expenses to its directors and officers as incurred in connection with legal proceedings against them for which they may be indemnified; and
- the rights conferred in the amended and restated bylaws are not exclusive.

The Registrant has entered into indemnification agreements with each of its directors and certain officers. These agreements, among other things, require the Registrant to indemnify each director and officer to the fullest extent permitted by Delaware law, including indemnification for expenses such as attorneys' fees, judgments, fines and settlement amounts incurred by the director or officer in any action or proceeding, including any action by or in the right of the Registrant, arising out of the person's services as a director or officer of the Registrant, any subsidiary of the Registrant or any other company or enterprise to which the person provides services at the Registrant's request. The Registrant believes that its charter and bylaws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.

**Item 7. Exemption from Registration Claimed.**

Not Applicable.

**Item 8. Exhibits.**

<u>Exhibit Number</u>	<u>Description of Document</u>
3.1	<a href="#">Fourth Amended and Restated Certificate of Incorporation of Seattle Genetics, Inc. (1)</a>
3.2	<a href="#">Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of Seattle Genetics, Inc. (2)</a>
3.3	<a href="#">Amended and Restated Bylaws of Seattle Genetics, Inc. (3)</a>
4.1	Reference is made to Exhibits <a href="#">3.1</a> , <a href="#">3.2</a> and <a href="#">3.3</a>
4.2	<a href="#">Specimen Common Stock Certificate (4)</a>
5.1+	<a href="#">Opinion of Cooley LLP</a>
23.1+	<a href="#">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm for Seattle Genetics, Inc.</a>
23.2+	<a href="#">Consent of Ernst &amp; Young, LLP, independent registered public accounting firm for Cascadian Therapeutics, Inc.</a>
23.3+	<a href="#">Consent of Cooley LLP (included in Exhibit 5.1)</a>
24.1+	<a href="#">Power of Attorney (included in the signature page hereto)</a>
99.1	<a href="#">Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan (5)</a>

(1) Previously filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 000-32405, filed with the Commission on November 7, 2008 and incorporated herein by reference.

- 
- (2) Previously filed as an exhibit to the Registrant's Current Report on Form 8-K, File No. 000-32405, filed with the Commission on May 26, 2011 and incorporated herein by reference.
  - (3) Previously filed as an exhibit to the Registrant's Current Report on Form 8-K, File No. 000-32405, filed with the Commission on November 25, 2015 and incorporated herein by reference.
  - (4) Previously filed as an exhibit to the Registrant's Registration Statement on Form S-1/A, File No. 333-50266, filed with the Commission on February 8, 2001 and incorporated herein by reference.
  - (5) Previously filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, File No. 000-32405, filed with the Commission on July 26, 2018 and incorporated herein by reference.

+ Filed herewith

**Item 9. Undertakings.**

1. The undersigned Registrant hereby undertakes:

(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

*Provided, however,* that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference herein.

(b) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

- 
3. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington on July 26, 2018.

**SEATTLE GENETICS, INC.**

By: /S/ CLAY B. SIEGALL, PH.D.  
Clay B. Siegall, Ph.D.  
President and Chief Executive Officer

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Clay B. Siegall, Todd E. Simpson and Jean Liu, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the "SEC"), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/S/ CLAY B. SIEGALL, PH.D.</u> Clay B. Siegall, Ph.D.	President, Chief Executive Officer and Director <i>(Principal Executive Officer)</i>	July 26, 2018
<u>/S/ TODD E. SIMPSON</u> Todd E. Simpson	Chief Financial Officer <i>(Principal Accounting and Financial Officer)</i>	July 26, 2018
<u>/S/ SRINIVAS AKKARAJU, M.D., PH.D.</u> Srinivas Akkaraju, M.D., Ph.D.	Director	July 26, 2018
<u>/S/ FELIX BAKER, PH.D.</u> Felix Baker, Ph.D.	Director	July 26, 2018
<u>/S/ DAVID W. GRYSKA</u> David W. Gryska	Director	July 26, 2018
<u>/S/ MARC E. LIPPMAN, M.D.</u> Marc E. Lippman, M.D.	Director	July 26, 2018
<u>/S/ JOHN A. ORWIN</u> John A. Orwin	Director	July 26, 2018

---

/S/ ALPNA SETH  
Alpna Seth

Director

July 26, 2018

/S/ NANCY A. SIMONIAN, M.D.  
Nancy A. Simonian

Director

July 26, 2018

/S/ DANIEL G. WELCH  
Daniel G. Welch

Director

July 26, 2018



July 26, 2018

Seattle Genetics, Inc.  
21823 30th Drive SE  
Bothell, WA 98021

Ladies and Gentlemen:

We have represented Seattle Genetics, Inc., a Delaware corporation (the "**Company**"), in connection with the filing of a Registration Statement on Form S-8 (the "**Registration Statement**") with the Securities and Exchange Commission covering the offering of up to 6,000,000 shares of the Company's Common Stock, par value \$0.001 per share (the "**Shares**"), pursuant to the Company's Amended and Restated 2007 Equity Incentive Plan (the "**Plan**"), and the Company has requested our opinion in connection with certain related matters.

In connection with this opinion, we have examined the Registration Statement and related Prospectus, the Company's Fourth Amended and Restated Certificate of Incorporation, as amended to date, and Amended and Restated Bylaws, as currently in effect, the Plan and such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion. We have assumed the genuineness and authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies thereof.

Our opinion is expressed only with respect to the federal laws of the United States of America and the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, and the Registration Statement and related Prospectus, will be validly issued, fully paid and nonassessable.

We consent to the filing of this opinion as an exhibit to the Registration Statement.

Sincerely,

COOLEY LLP

By: /s/ Chadwick L. Mills  
Chadwick L. Mills

Cooley LLP 101 California Street 5th Floor San Francisco, CA 94111-5800  
t: (415) 693-2000 f: (415) 693-2222 cooley.com

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Seattle Genetics, Inc. of our report dated February 14, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Seattle Genetics, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2017.

/s/ PricewaterhouseCoopers LLP

Seattle, Washington  
July 26, 2018

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Seattle Genetics, Inc. of (1) our report dated March 9, 2017, with respect to the consolidated financial statements of Cascadian Therapeutics, Inc. as of December 31, 2016 and 2015 and for each of the three years ended December 31, 2016, incorporated by reference in Seattle Genetics, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 31, 2018, and (2) our report dated March 8, 2018, with respect to the consolidated financial statements of Cascadian Therapeutics, Inc. as of December 31, 2017 and 2016 and for each of the three years ended December 31, 2017, incorporated by reference in Seattle Genetics, Inc.'s Current Report on Form 8-K, as amended, filed with the Securities and Exchange Commission on May 21, 2018.

/s/ Ernst & Young LLP

Seattle, Washington  
July 23, 2018